Biological treatment of juvenile rheumatoid arthritis
Abstract
In this article the biological therapy of juvenile rheumatoid arthritis is represented by new class of drugs. Genetically engineered biological drugs are allowed to use in pediatric rheumatology: etanercept, adalimumab, abatacept, tocilizumab.
About the Authors
A. M. Ammosova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
E. I. Alekseeva
Научный центр здоровья РАМН;
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
M. V. Handu
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
V. M. Argunova
РБ№1-НЦМ МЗ РС(Я)
Russian Federation
Russian Federation
S. J. Artamonova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
N. M. Zakharova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
S. V. Markova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
Ja. A. Munhalova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
L. A. Stepanova
МИ СВФУ им. М.К. Аммосова
Russian Federation
Russian Federation
References
1. Adalimumab: new opportunities of rheumatoid arthritis treatment / E.I. Alekseeva, A.O. Lisitsyn, N.A. Karagulyan [et al.] / / Current Pediatrics. - 2009. - №8 (3). - P. 88-94.
2. Alekseyeva E.I. Juvenile rheumatoid arthritis. Etiology. Pathogenesis. Clinic. Algorithms for diagnosis and treatment: guide for doctors, teachers, researchers / Ye.I. Alekseyeva, P.F. Litvitsky; Ed. Acad. Academy of Medical Sciences, Prof. A.A. Baranov // M., 2007. - P. 325-339.
3. Biological therapy in pediatric rheumatology / A.A. Baranov, E.I. Alekseyeva, S.I., Valiyeva, T.M. Bzarova / / Bulletin of the Russian Academy of Medical Sciences. - 2011. - № 6.
4. Infliximab effect on clinical and laboratory activity parameters in cases of various juvenile arthritis variants / E.I. Alekseyeva, A.M. Alekseyeva, S.I. Valiyeva [et al.] // Current Pediatrics. - 2008. - №7 (2) - P. 42-54.
5. Soluble TNF receptors in the treatment of juvenile idiopathic arthritis / T.M. Bzarova, E.I. Alekseyeva, A.N. Fetisova [et al.] / / Current Pediatrics. - 2012. - №11 (4). - P. 29-37.
6. New advantages of various juvenile arthritis therapy with monoclonal antibodies to receptor interleukin 6 / E.I. Alekseyeva, Denisova R.V.,Valiyeva S.I. [et al.] // Current Pediatrics. - 2010. - №9 (1). - P.52-61.
7. Effectiveness of infliximab in patients with juvenile ankylosing spondylarthritis / E.I. Alekseyeva, A.L. Kozlova, S.I. Valiyeva [et al.] // Current Pediatrics. - 2009. - №8 (2). - P. 20-26.
8. Effectiveness and safety of repeated courses of treatment with rituximab in patients with severe refractory idiopathic arthritis / E.I. Alekseeva, S.I. Valiyeva, T.M. Bzarova [et al.] / / Current Pediatrics. - 2009. - №8 (5). - P. 19-30.
9. A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) http://clinicaltrials.gov/ct2/show/.
10. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition / M.C. Genovese, J.C. Becker, M. Schiff [et al.] // N. Engl. J. Med. – 2005. – 353. – Р. 1114–1123.
11. Abatacept in children with juvenile idiopathic arthritis: a double-blind, placebocontrolled withdrawal trial / N. Ruperto, D.J. Lovell, P. Quartier [et al.] // The Lancet. – 2008. – № 372. - Р. 383-391.
12. Adalimumab in the therapy of uveitis in childhood / S. Biester, C. Deuter, H. Michels [et al.] // Br. J. Ophthalmol. – 2007. – № 91. – Р.319–324.
13. Adalimumab in juvenile idiopathic arthritisassociated chronic anterior uveitis / P. Tynjälä, K. Kotaniemi, P. Lindahl [et al.]: // Rheumatology (Oxford). - 2008. – № 47. – Р. 339–344.
14. Anakinra in the treatment of polyarticularcourse juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study / N. Ilowite, O. Porras, A. Reiff et al.// Clin. Rheumatol. – 2009. - № 28(2). - Р. 129–137.
15. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series / P.A. Nigrovic, M. Mannion, F.H. Prince, A. Zeft [et al.] // Arthritis Rheum. – 2011. - №63 (2). – Р. 545- 55. doi: 10.1002/art.30128.
16. Disease remission is achieved within two years in over half of methotrexate naïve patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract] / R. Westhovens, M. Robles, S. Nayiager [et al.] // Arthritis Rheum. - 2009. - № 60(Suppl. 10). – Р. 638.
17. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study / F.H. Prince, M. Twilt, N.C. Jansen-Wijngaarden, L.W. van Suijlekom-Smit. // Ann. Rheum. Dis. – 2007. - № 66(5) – Р. 704–705.
18. El-Gabalawy H.D. Why do we not have a cure for rheumatoid arthritis? / H.D. El-Gabalawy, P.E. Lipsky // Arthritis Reum. – 2002. – № 4 (Suppl. 3). – P. 297-301.
19. Feito J.G. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF-alpha antagonists / J.G. Feito, C.A. Pereda // J. Clin. Rheumatol. – 2009. - № 15(7). – Р. 363–365.
20. Golimumab in patients with active rheumatoid arthritis despite treatment with Methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study / J. Kay, E.L. Matteson, B. Dasgupta [et al.] // Arthritis Rheumatism – 2008. – № 58. – Р. 964–975.
21. GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosisin patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial / J.S. Smolen, J. Kay, M.K. Doyle [et al.]// Lancet. – № 374 - Р. 210–221.
22. IL-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France / T. Lequerre, P. Quartier, D. Rosellini [et al.] // Ann. Rheum. Dis. – 2008. – № 67. – Р. 302–308.
23. Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials / S. Yokota, T. Imagawa, T. Miyamae, M. Mori [et al.] // Arthritis Rheum. – 2008. – № 58. - S631.
24. Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement / P. Woo, N. Wilkinson, A.M. Prieur [et al.]: // Arthritis Res. Ther. – 2005. – № 7. – Р. 1281–1288.
25. Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis / D.J. Lovell, A. Reiff, N.T. Ilowite [et al.] // Arthritis Rheum. – 2008. - №58 (5). – Р. 1496-1504.
26. Pediatric Rheumatology Collaborative Study Group Pediatric Rheumatology International Trials Organisation. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis / D.J. Lovell, N. Ruperto, S. Goodman [et al.] // N. Engl. J. Med. – 2008. – 21359 (8). - Р. 810–820.
27. Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) A service of the U.S. National Institutes of Health.
28. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease / W.J. Sandborn, B.G. Feagan, S. Stoinov [et al.] // N. Engl. J. Med. – 2007. - 19357(3), Р. 228–238.
29. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial / E.C. Keystone, A.F. Kavanaugh, J.T. Sharp [et al.] // Arthritis Rheum. – 2004. – №50 - Р. 1400–1411.
30. Rituximab therapy for refractory systemiconset juvenile idiopathic arthritis / J. Narváez, C. Díaz-Torné, X. Juanola [et al.]: // Ann. Rheum. Dis. – 2009. - № 68(4). – Р. 607–608.
31. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade / J.S. Smolen, C. Han, D.M. van der Heijde [et al.] // Ann. Rheum. Dis. – 2009. - № 68 (6). – Р.823-827.
32. Retrospective clinical study on the nobable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) / T. Takeuchi, H. Yamanaka, E. Inoue [et al.] // Mod. Rheumatol. – 2008. - № 18 (5) - Р. 447–454.
33. Rituximab: A promising alternative in the treatment of systemic onset rheumatoid idiopathic arthritis (soJIA) when anti-TNF fails / CAP Testa, J.G. Feito, C.M. Arquillo // Ann. Rheum. Dis. – 2007. - № 66(Suppl. 2). - AbsSAT0415.
34. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report / M. KasherMeron, Y. Uziel, H. Amital // Rheumatology (Oxford). – 2009. - № 48(4). – Р. 445–446.
35. Textbook of paediatric rheumatology, 2nd end. / Cassidy J., Petty R., eds. // New York: Churchill Livigstone – 1989.
Review
For citations:
Ammosova A.M., Alekseeva E.I., Handu M.V., Argunova V.M., Artamonova S.J., Zakharova N.M., Markova S.V., Munhalova J.A., Stepanova L.A. Biological treatment of juvenile rheumatoid arthritis. Yakut Medical Journal. 2012;(4):79-82. (In Russ.)
Views:
1
Email this article 